

AIM ITALY: PHARMANUTRA IN THE TOP 10 FOR PERFORMANCE AND CAPITALISATION

Pisa, 14th December 2018 - [PharmaNutra S.p.A.](#), a pharmaceutical company that leads the market in the iron-based nutritional supplements sector, listed on the AIM Market Italy since 18th July 2017, has recorded the umpteenth positive Stock Market capitalisation performance.

An article published on last 6 December by the influential, economic-financial daily, Milano Finanza, lists the first 20 companies for capitalisation and the first 20 stock performances, measured from their debut value on AIM Italy, the Alternative Investment Market of the Italian Stock Exchange which includes 114 companies, mainly innovative SMEs, for a total capitalisation of €7.5 billion.

An official ranking smiling at the Italian company founded in 2003 by the brothers Andrea and Roberto Lacorte, ranking eighth amongst the main ones for capitalisation, with €153.4 million out of a turnover of 37.5 million, and ranking tenth amongst the best performers, with a positive 55.90% variation (source Bloomberg and processing MF database).

These figures are extremely positive and a tangible signal of investors' full trust in PharmaNutra S.p.A.. Thanks to its constant production and marketing of innovative, patented pharmaceutical and nutraceutical products, with proprietary raw materials, the company is rapidly gaining important market shares, both in Italy and abroad.

Roberto Lacorte, Vice President of PharmaNutra, declares: *“The financial performances highlighted by Milano Finanza - that we are particularly proud of - are the concrete result of a winning company strategy that continues to guarantee important results. They are also due to a concrete development base on which to found further growth considering the strong fundamentals soon to be released by the company and further assets about to be finalised. It is an important acknowledgement and an objective Group solidity indicator, that I am pleased to be able to share with our workforce, always the company's crowning achievement; and with the investors who, from when we were first listed on the Stock Market, have believed in us and in our industrial policy”.*

PharmaNutra S.p.A.

Founded and led by President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 79 of them published and with more than 6000 subjects treated with the supplements. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. <http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@PharmaNutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com